RAG-17 is an experimental RNA-targeting therapy designed to lower toxic SOD1 protein in people with SOD1-ALS. A six-person trial found RAG-17 was well tolerated, with no serious side effects. RAG-17 ...

Study examines Qalsody safety after approval “This study is the first to systematically conduct a post-marketing [safety] ...

Although I continue to rely on a rollator to help me walk inside the house and a mobility scooter when I’m out and about, getting the power wheelchair was a strategic, planning-ahead decision. I live ...

Preventing TDP-43 from forming toxic clumps is widely seen as a promising strategy for developing new ALS treatments. But it’s been difficult for scientists to find a way to prevent these clumps ...

A PBS documentary, "Loving John," explores a gay American Samoan man's final years with ALS. It highlights the disease's ...

Over the last five years, Canadian ALS clinics have shifted from offering genetic testing mainly to people with a family ...

A self-balancing robotic exoskeleton was found safe and feasible for ALS patients with gait impairment. It helps patients practice walking hands-free, improving mobility, posture, and well-being.

I walked with our dog, Comet, on a trail in the woods behind our house. The woods felt cool out of the hot sun. Light filtered through the trees overhead as I breathed in the rich smell of summer ...

Australian data links over 10% of ALS cases to known genetic mutations. The SALSA-SGC consortium collects data to understand ALS causes and progression. The project brings together seven major motor ...

An expanded access program for Qalsody in ALS patients was feasible and well-tolerated. The program provided Qalsody to 11 ALS patients ineligible for trials. A mixed funding model, including ...

Amyotrophic lateral sclerosis (ALS) is a progressive neurological disease that affects people differently, with ALS prognosis varying considerably from one person to another. The condition gradually ...